Wijemanne Subhashie, Ondo William
Department of Neurology, University of Texas Health San Antonio, San Antonio, Texas, USA.
Department of Neurology, Weill Cornell Medical School, Methodist Neurological Institute, Houston, Texas, USA.
Pract Neurol. 2017 Dec;17(6):444-452. doi: 10.1136/practneurol-2017-001762. Epub 2017 Nov 2.
Restless legs syndrome (RLS) is a chronic neurological disorder that interferes with rest and sleep. It has a wide spectrum of symptom severity, and treatment is started when symptoms become bothersome. Dopamine agonists and calcium channel apha-2-delta antagonists (gabapentin, gabapentin enacarbil and pregabalin) are first-line treatments; calcium channel alpha-2-deltas are preferred over dopamine agonists because they give less augmentation, a condition with symptom onset earlier in the day and intensification of RLS symptoms. Dopamine agonists can still be used as first-line therapy, but the dose should be kept as low as possible. Iron supplements are started when the serum ferritin concentration is ≤75 µg/L, or if the transferrin saturation is less than 20%. For severe or resistant RLS, a combined treatment approach can be effective. Augmentation can be very challenging to treat and lacks evidenced-based guidelines.
不宁腿综合征(RLS)是一种干扰休息和睡眠的慢性神经障碍。其症状严重程度范围广泛,当症状变得令人烦恼时开始治疗。多巴胺激动剂和钙通道α-2-δ拮抗剂(加巴喷丁、普瑞巴林)是一线治疗药物;钙通道α-2-δ拮抗剂比多巴胺激动剂更受青睐,因为它们引起的症状加重较少,症状加重是指症状在一天中更早出现且不宁腿综合征症状加剧的情况。多巴胺激动剂仍可作为一线治疗,但剂量应尽可能低。当血清铁蛋白浓度≤75μg/L或转铁蛋白饱和度低于20%时开始补充铁剂。对于严重或难治性不宁腿综合征,联合治疗方法可能有效。治疗症状加重非常具有挑战性,且缺乏循证指南。